Subscribe to Search results

Dr Pettigrew noted during her hearings at the Inquiry that Dr Willoughby did not have any conversations with her about the risk of NANB Hepatitis and was not aware of NANB as a concept until liver biopsies were carried out on her haemophilia patients in 1984.

Published on:

Dr Pettigrew noted that there was no system from senior doctors of updating junior doctors with updates about medical and clinical developments

Published on:

Dr Pettigrew did not raise or discuss AIDS with Dr Willoughby in 1982 as Dr Pettigrew herself did not become aware of haemophiliacs contracting AIDS until 1983 and Dr Willoughby did not make her aware of this.

Published on:

Dr Pettigrew asserted that there was no steps taken while Dr Willoughby was director to reduce or minimise the risk of patients being infected with Hepatitis or AIDS.

Published on:

Dr Pettigrew noted that reliability of supply was a factor in Dr Willoughby's thinking noting that commercial concentrates tended to be used on home therapy and NHS for patients that were not.

Published on:

Dr Willoughby acted autonomously and did not communicate with the Royal Infirmary.

Published on:

There was no policy at Royal Hospital for Sick Children in Glasgow to inform parents about the risks of HIV and in relation to Hepatitis risks, the focus was on Hepatitis B.

Published on:

Dr Pettigrew admitted that tests were undertaken using stored samples when patients weren't aware that samples of their sera or their child's sera was being stored. In her testimony to the Inquiry, Dr Pettigrew asserted this practice took place at the Royal Hospital for sick children.

Published on:

Dr Anna Pettigrew took up post as a part-time clinical assistant at the Royal Hospital for Sick Children.

Published on:

Dr Pettigrew recollected that newly diagnosed patients or those with mild haemophilia were treated with cryoprecipitate and those on home therapy or frequent attending patients were treated with concentrate.

Published on:

Dr Pettigrew recalled commercial product was more user friendly and dissolved quicker.

Published on:

Parents often administered home therapy which was preferred.

Published on:

Home therapy and prophylactic therapy were introduced by Dr Willoughby for psychological and clinical reasons.

Published on:

Dr Pettigrew viewed that all clinical staff acted in what they thought to be in the best interests of their patients, including Dr Willoughby (who instituted home therapy with Factor VIII concentrates.

Published on:

Cryoprecipitate, although less convenient to use, was not impracticable for home treatment despite what the opinion at Yorkhill hospital was.

Published on:

Glasgow Yorkhill Haemophilia Centre's annual returns showed substantial but decreasing use of commercial compared to PFC concentrates.

Published on:

RHSC annual return showed 62,315 units of commercial concentrate was used for haemophilia treatment.

Published on:

RHSC annual return showed 123,998 units of commercial concentrate was used for haemophilia treatment.

Published on:

RHSC annual return showed 354,276 units of commercial concentrate was used for haemophilia treatment.

Published on:

RHSC annual return showed 682,732 units of commercial concentrate was used for haemophilia treatment.

Published on: